Sign In
Section Navigation
Common TitleGS-366-1160
Official Title A Phase 3b, Randomized, Double-Blind Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/ Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Subjects
Phase Phase IIIB
ClinicalTrials.gov NCT02345226
Treatments
Tenofovir alafenamide-Emtricitabine
Tenofovir alafenamide-Emtricitabine Descovy

Tenofovir alafenamide-Emtricitabine

Tradename:DescovyOther Names:TAF-FTCClass:Nucleoside Reverse Transcriptase Inhibitors (NRTI)
,
Rilpivirine-Tenofovir alafenamide-Emtricitabine
Rilpivirine-Tenofovir alafenamide-Emtricitabine Odefsey

Rilpivirine-Tenofovir alafenamide-Emtricitabine

Tradename:OdefseyOther Names:RPV-TAF-FTCClass:Single-Tablet Regimens
Funding
IndustryGilead Sciences

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.